When delivered through gene therapy, this receptor antagonist could significantly diminish the expression of MMP1, MMP3, MMP13 and ADAMTS4, as well as the activity of these enzymes in the NP and the AF, by more than 95%41. This evidence concerns the gene MMP13 and atrial fibrillation.